How Do They Work?

Both drugs target two hormone pathways, but they do it differently.

MariTide

MariTide is a two-in-one molecule:

1. It blocks the GIP receptor. The idea is that this nudges your body toward burning more fat.
2. It activates the GLP-1 receptor, which reduces appetite and slows digestion.

Blocking one pathway while activating the other is the novel piece. Nothing else on the market does this.

Mounjaro (tirzepatide)

Mounjaro takes a different angle:

1. It activates both GIP and GLP-1 receptors.
2. That combination helps control blood sugar, lowers appetite, and may bump up energy use.

The Key Difference

MariTide blocks GIP. Mounjaro activates it. Both activate GLP-1. Which approach is better for weight loss is still an open question. The trials haven't been head-to-head yet.

How Well Do They Work?

MariTide: Phase 1 and Phase 2 Results

MariTide now has reported Phase 2 data, but it is still investigational.

• Phase 2 obesity data reported up to about 20% average weight loss at week 52 in people without type 2 diabetes.
• In people with type 2 diabetes, reported weight loss was up to about 17% with HbA1c reductions up to 2.2 percentage points.
• Earlier Phase 1 data showed rapid early weight loss and a sustained effect after dosing stopped.

Those findings are promising, but MariTide still lacks completed Phase 3 trials, regulatory approval, and head-to-head trials against Mounjaro or Zepbound.

Mounjaro: Proven Track Record

Mounjaro has been through larger trials and is approved for type 2 diabetes in Canada and the U.S.:

• In the main weight loss trial, average weight loss was 15% to 21% over 72 weeks.
• The 15mg dose got the best results.
• Results outperformed Ozempic in head-to-head comparisons.

Comparing the Two

A few caveats before you draw conclusions:

• MariTide has reported Phase 1 and Phase 2 data, but no completed Phase 3 program or approval. Mounjaro has completed Phase 3 trials.
• The trial designs and populations still differ, and the two drugs have not been compared head to head.
• MariTide's sustained effect after stopping is the unique finding. Mounjaro doesn't show this.

Mounjaro is the more proven drug. MariTide's potential is interesting, but it still has to clear Phase 3 and regulatory review.

Dosing and Side Effects

MariTide

• Subcutaneous injection.
• Possibly monthly dosing, or less often.
• Trials suggest the dose can be tapered down over time.

Side effects reported in trials:

• Mild nausea and vomiting, typical for GLP-1 drugs.
• Generally well tolerated.
• Long-term effects still unknown.

Mounjaro

• Subcutaneous injection, once a week.
• Starts at a low dose and titrates up.

Side effects:

• Nausea, diarrhea, vomiting, constipation, abdominal pain.
• Usually mild to moderate and they improve over time.
• Rare serious risks include pancreatitis and thyroid tumours.

The Practical Differences

1. Frequency. Monthly MariTide vs weekly Mounjaro.
2. Long-term safety data. Mounjaro has it. MariTide doesn't yet.
3. Tapering. MariTide may allow it. Mounjaro doesn't.

Convenient dosing matters, but safety and effectiveness matter more. Phase 3 and longer follow-up will tell us if the early advantages hold up.

What Stands Out About Each Drug

MariTide: The Sticky Effect

1. Weight loss persisted up to 150 days after the last dose in early trials.
2. Possibly monthly dosing instead of weekly.
3. The mechanism is novel: GIP blockade plus GLP-1 activation.

If those features hold up in Phase 3 and real-world data, MariTide could shift obesity treatment from continuous medication to periodic "top-ups."

Mounjaro: The Proven Option

1. Some of the highest average weight-loss numbers among incretin-based medicines.
2. Works for both diabetes and weight loss. Useful since the two conditions often overlap.
3. Approved for type 2 diabetes with a better-characterised safety profile.

Mounjaro is already reshaping diabetes care and is on track to become the standard in medical weight loss.

What This Means for Obesity Treatment

• More effective drugs in the toolkit.
• More room to match the drug to the patient.
• A clearer recognition that obesity is a chronic condition that needs ongoing management.
• Maybe less stigma as treatment options become normal medical practice.

The Bigger Picture

Drugs aren't the whole answer. Diet, exercise, and behavioural change still matter. But the medication side of weight management has gotten genuinely better over the last few years, and it's about to get better still.

If you're weighing options, talk to a clinician who knows your full medical picture.

Disclaimer: This blog post is intended for educational purposes only and should not be taken as medical advice. Always consult your healthcare provider for personal health concerns.